<DOC>
	<DOCNO>NCT02549391</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety KHK7580 orally administer daily 30 week subject secondary hyperparathyroidism ( SHPT ) receive hemodialysis randomize , double-blind , intra-subject dose-adjustment , parallel-group design cinacalcet hydrochloride active control .</brief_summary>
	<brief_title>Phase 3 Study KHK7580</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Personally submit write voluntary inform consent participate study Stable chronic renal disease treat hemodialysis 3 time weekly least 12 week screen Mean intact PTH level &gt; 240 pg/ml screening , 2 week 1 week start study treatment Treatment cinacalcet hydrochloride within 2 week screening ; Change dose dose regimen activate vitamin D drug derivative , phosphate binder , calcium preparation within 2 week screen ; start treatment drug within 2 week screen ; Parathyroidectomy and/or parathyroid intervention within 24 week screen ; Severe heart disease ; Severe hepatic dysfunction ; Uncontrolled hypertension and/or diabetes ; Treatment investigational product ( drug medical device ) clinical study study equivalent clinical study within 12 week screen ; Primary hyperparathyroidism ; Other condition unfit participation study discretion investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>